All News

New legislation could be a model for other states.

23andMe recently gained FDA approval, but will it actually help keep people healthier?

The chain has said it remains committed to buying Rite Aid stores.

A reporter earned the biggest journalism prize covering the opioid crisis.

Supervalu’s diabetes campaign offers risk assessments, screening, and food education.

New class of glucose-lowering agents lowers hospitalization and death rates even in Type 2 patients without heart disease.

Trump and Gottlieb are both taking steps to end the opioid epidemic. But is it enough?

Small Doses is news for pharmacists in a way that works for you.

What the new company will mean for specialty pharmacy.

Nearly 600,000 inhalers are being recalled.

Two previous reports of device failures lead EpiPen maker to expand recall to the United States.

What we know-and what we don't-about antibiotics in America.

Even medical marijuana has health-care costs and outcomes.

How a program hopes to cut errors in half.

Ontario joins Nova Scotia in making medication dispensing error reporting mandatory, but no states have enacted similar laws.

Taking a clear-eyed look at the cost of health care can reduce waste.

Biosimilars, cancer drugs, and orphan drugs are heading towards FDA approval in 2017.

What New York City is doing to curb the opioid epidemic.

This year's meeting highlighted the opioid epidemic and ways pharmacists can improve patient care.

This week, take a look at studies and news on supplements, depression, opioids, and more. Small doses is the news you need in a way that works for you.

DIR fees and health-care reform will lead pharmacists’ legislative concerns.

It's still early in 2017, but the FDA has been approving drugs left and right. Here's what you need to know.

Two device failures lead Mylan to recall more than 80,000 EpiPens overseas.

A pill-like device that pumps vaccine into the mouth may make syringes obsolete.

Over 55 years, 450,000 people stayed alive and 200 million people stayed well in the United States because of vaccines.

There is finally a one-stop resource available preceptor development.

In the battle against ADEs, pharmacists are leading the way.

New board members are helping to keep our publication great.